Cyclosporine a immunosuppression in sheep with response enhancement by concomitant ketoconazole

被引:4
作者
ODonoghue, HL
Penhale, WJ
Manning, LS
Reynoldson, JA
Turner, JH
机构
[1] FREEMANTLE HOSP,DEPT NUCL MED,FREMANTLE,WA,AUSTRALIA
[2] FREEMANTLE HOSP,CELL BIOL RES UNIT,FREMANTLE,WA,AUSTRALIA
[3] MURDOCH UNIV,SCH VET STUDIES,MURDOCH,WA 6150,AUSTRALIA
关键词
cyclosporine A; immunosuppression; ketoconazole; pharmacokinetics; sheep;
D O I
10.1111/j.1440-1681.1996.tb01182.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The pharmacokinetics of a single dose of Cyclosporine A (CsA) administered to sheep by intravenous (i.v.) route were examined. 2. Concomitant administration of ketoconazole was found to increase the area under the blood CsA concentration-tine curve (AUG) and was effective when adminstered by the oral or intraperitoneal route. 3. The effects of CsA and ketoconazole on the immune system of sheep were also assessed. 4. A single dose of CsA 5 mg/kg resulted in abrogation of in vitro lymphocyte function manifest at 24 h after injection of CsA. Normal responsiveness recovered in 48-72 h. Numbers of T lymphocytes in peripheral blood were elevated transiently at 48 h although no other significant alteration in lymphocyte subsets was observed with this treatment. 5. Concomitant ketoconazole administration enhanced the CsA-induced suppression of in vitro lymphocyte responses. Blood levels of CsA (AUG values to 24 h) were significantly elevated with concomitant ketoconazole administration and depression of lymphocyte responses to mitogens were also significantly enhanced. An increase in the proportion of T4 positive cells in the blood was observed at 48 h and at 7 days after administration of CsA with ketoconazole. 6. These findings indicate that CsA effectively abrogates immunocompetence in the sheep and this immunosuppressive effect is enhanced by concomitant administration of ketoconazole.
引用
收藏
页码:797 / 803
页数:7
相关论文
共 28 条
[1]   ONSET AND DEVELOPMENT OF CYCLOSPORINE-A EFFECTS ON LYMPHOCYTES OF CARDIAC PATIENTS BEFORE HEART-TRANSPLANTATION [J].
ALBENGRES, E ;
RIANT, P ;
MOREL, M ;
HAMBERGER, C ;
TAVOLARO, O ;
LOISANCE, D ;
TILLEMENT, JP ;
CACHERA, JP .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :2-7
[2]   PHARMACODYNAMICS OF CYCLOSPORINE-KETOCONAZOLE INTERACTION IN MICE - COMBINED THERAPY POTENTIATES CYCLOSPORINE IMMUNOSUPPRESSION AND TOXICITY [J].
ANDERSON, JE ;
MORRIS, RE ;
BLASCHKE, TF .
TRANSPLANTATION, 1987, 43 (04) :529-533
[3]  
BOREL JF, 1989, PHARMACOL REV, V41, P259
[4]  
BOZKURT F, 1987, CLIN NEPHROL, V28, P10
[5]  
BUTMAN SM, 1991, J HEART LUNG TRANSPL, V10, P351
[6]   PHARMACOKINETICS AND ABSOLUTE BIOAVAILABILITY OF CYCLOSPORINE FOLLOWING INTRAVENOUS AND ABOMASAL ADMINISTRATION TO SHEEP [J].
CHARLES, BG ;
FILIPPICH, LJ ;
PASS, MA .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1993, 45 (09) :821-824
[7]  
DIPADOVA FE, 1989, PHARMACOL REV, V41, P373
[8]  
DMELLO A, 1989, RES COMMUN CHEM PATH, V64, P441
[9]  
FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3
[10]   CYCLOSPORINE DOSE REDUCTION BY KETOCONAZOLE ADMINISTRATION IN RENAL-TRANSPLANT RECIPIENTS [J].
FIRST, MR ;
SCHROEDER, TJ ;
ALEXANDER, JW ;
STEPHENS, GW ;
WEISKITTEL, P ;
MYRE, SA ;
PESCE, AJ .
TRANSPLANTATION, 1991, 51 (02) :365-370